|
Aileron Therapeutics, Inc. (ALRN) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Aileron Therapeutics, Inc. (ALRN) Bundle
Looking to assess the intrinsic value of Aileron Therapeutics, Inc.? Our (ALRN) DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -29.8 | -20.3 | -26.5 | -27.5 | -15.6 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .2 | .2 | .1 | .2 | .1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -30.0 | -20.5 | -26.6 | -27.6 | -15.7 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 18.3 | 13.8 | 45.9 | 21.2 | 17.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.5 | 1.6 | 1.2 | 1.7 | 1.2 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.2 | .0 | -.2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -29.4 | -21.1 | -26.2 | -27.3 | -15.7 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -27.9 | -20.8 | -26.6 | -26.6 | -16.1 | -1.2 | .0 | .0 | .0 | .0 |
| WACC, % | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 | 15.45 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -17 | |||||||||
| Equity Value | 16 | |||||||||
| Diluted Shares Outstanding, MM | 5 | |||||||||
| Equity Value Per Share | 3.53 |
What You Will Get
- Real ALRN Financial Data: Pre-filled with Aileron Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Aileron Therapeutics' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Financial Data: Obtain precise historical data and forecasts tailored for Aileron Therapeutics, Inc. (ALRN).
- Adjustable Forecast Parameters: Modify highlighted fields such as discount rates, growth projections, and profit margins.
- Real-Time Calculations: Automatic recalculations for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly graphs and summaries for clear visualization of your valuation outcomes.
- Designed for All Levels: An intuitive layout suitable for investors, financial officers, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Aileron Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Aileron Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Aileron Therapeutics, Inc. (ALRN) Calculator?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for Aileron Therapeutics.
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios for ALRN.
- Detailed Insights: Automatically computes Aileron’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide accurate foundations for analysis.
- Professional Quality: Perfect for financial analysts, investors, and consultants focused on biotechnology.
Who Should Use This Product?
- Investors: Assess Aileron Therapeutics’ valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and evaluate financial forecasts.
- Startup Founders: Understand the valuation processes of biotech firms like Aileron Therapeutics.
- Consultants: Provide comprehensive valuation analyses for clients in the healthcare sector.
- Students and Educators: Utilize current market data to learn and teach valuation strategies.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Aileron Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), incorporating parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models detailing intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Aileron Therapeutics, Inc. (ALRN).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to simplify result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.